OCOlga R. Chávez-Alexander-Anderson

Olga R. Chávez-Alexander-Anderson

*This is an algorithmically generated author record based on publicly available information.

Olga R. Chávez-Alexander-Anderson has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterization of Anti-Canine PD-1 Antibodies

    by Colin J. Hartman, Petra Sergent, Anna Barbara Emilia Zimmermann, Olga R. Chávez-Alexander-Anderson, Luis A. Perez Alonso, Louise Lines, Juan Carlos Pinto-Cárdenas, Daniel Luna Dávalos, Anna M. Schmoker, Scott M. Palisoul, et al.

    Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.